Home Page

Emergent is dedicated to one simple
mission—to protect and enhance life.

As a global specialty life sciences company,
Emergent is  focused on providing specialty products
for civilian and military populations that address
intentional and naturally emerging public health threats.

Learn More

Emergent BioSolutions Awarded
BARDA Contract for Advanced
Development and Delivery of NuThrax,
a Next Generation Anthrax Vaccine,
Valued at Up to $1.6 Billion

LEARN MORE ▶

CDC Exercises Option to Procure
All Remaining Doses of BioThrax
Under 2011 Procurement Contract

No-cost Extension Enables Delivery by
November 30, 2016

LEARN MORE ▶

Emergent BioSolutions
Receives FDA Approval
for Large-Scale Manufacturing
of BioThrax in Building 55

LEARN MORE ▶

Our corporate social
responsibility efforts
are a key part of our
mission to protect and
enhance life for millions
around the world.

VIEW OUR ONLINE
CSR REPORT
 ▶
>

Meet Us

  • CPhI Worldwide

    CPhI Worldwide
    Barcelona, Spain
    October 4-6

     

  • BioProcess International Conference

    BioProcess International
    Boston, MA
    October 4-7

     

  • Investor Relations

    Check back soon for upcoming investor conferences

     

Price $31.60 3.84 (13.83%)
 Sep 30 2016 2:11PM

REFRESH